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Oral tablets are the predominant route of administration
for the acute treatment of migraine. Gastric Stasis (GS) is
commonly associated with migraine, and can significantly
alter the rate of intestinal absorption of an oral tablet, lead-
ing to inconsistent response to the administered drug. The
Tmax of a triptan administered as a tablet can vary from
25-120 min. MAP0004, an investigational drug that delivers
dihydroergrotamine (DHE) systemically via the lungs using
the TEMPO® inhaler, bypasses the gastrointestinal tract.
Consequently, GS is likely to have no effect on the absorp-
tion of drug into the bloodstream. MAP0004 administration
consistently achieves a DHE Tmax between 7-12 min. A
consistent Tmax, however, does not necessarily represent a
consistent clinical response. A retrospective analysis was
undertaken to determine whether pain relief rates were
consistent across the 1st, 5th, 15th and 25th headache
treated with MAP0004.
A total of 153 subjects within the open label, long term
safety study who had at least 25 qualifying migraines were
analyzed. Pain relief at 2 hours was seen on an average of
54.1%, and there was no significant difference when com-
paring subsequent migraines to the first qualifying
migraine or comparing the 1st, 5th, 15th and 25th all
together. Similarly, analysis of pain free values at 2 hours
(average=24%), sustained pain relief from 2-24 hours
(average=38.4%), and sustained pain free values from
2-24 hours (average=16.7%) were not statistically different
from the first qualifying migraine or comparing the 1st,
5th, 15th and 25th all together. In this retrospective analy-
sis, MAP0004 provided a consistent and similar response
rate in treating an episodic migraine attack, whether it was
the 1st, 5th, 15th or the 25th headache treated.
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